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Sex hormones have been implicated in neurite outgrowth, synaptogenesis, dendritic
branching, myelination and other important mechanisms of neural plasticity. Here we
review the evidence from animal experiments and human studies reporting interactions
between sex hormones and the dominant neurotransmitters, such as serotonin,
dopamine, GABA and glutamate. We provide an overview of accumulating data during
physiological and pathological conditions and discuss currently conceptualized theories
on how sex hormones potentially trigger neuroplasticity changes through these four
neurochemical systems. Many brain regions have been demonstrated to express
high densities for estrogen- and progesterone receptors, such as the amygdala, the
hypothalamus, and the hippocampus. As the hippocampus is of particular relevance
in the context of mediating structural plasticity in the adult brain, we put particular
emphasis on what evidence could be gathered thus far that links differences in behavior,
neurochemical patterns and hippocampal structure to a changing hormonal environment.
Finally, we discuss how physiologically occurring hormonal transition periods in humans
can be used to model how changes in sex hormones influence functional connectivity,
neurotransmission and brain structure in vivo.
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INTRODUCTION
Over the last decades, several lines of research have extended the
pivotal actions of ovarian hormones such as estrogen and pro-
gesterone outside of the reproductive tract. The brain represents
an important target for estrogen and progesterone effects. Both
hormones provide specific neuroendocrine conditions through
which brain structure and function are modulated across a
woman’s life span. The trophic effects of ovarian hormones
emerge early in brain development and remain throughout ado-
lescence (Juraska et al., 2013) and adulthood (Wise et al., 2008).
Many of these actions occur in brain regions involved in learning
(Hu et al., 2007) and memory (Liu et al., 2008), emotion (Amin
et al., 2006), motivation (Sakaki and Mather, 2012), motor con-
trol (Horstink et al., 2003), and cognition (Berman et al., 1997).
Furthermore, several lines of evidence support a main impact
of sex hormones on brain development and plasticity (Marino
et al., 2006). Specific structural effects of estrogen and proges-
terone include neurite outgrowth and synaptogenesis (Haraguchi
et al., 2012), dendritic branching (Cooke and Woolley, 2005) and
myelination (Garcia-Segura and Melcangi, 2006).
GENERAL MECHANISMS
Both estrogen and progesterone act via classical genomic recep-
tors as well as non-classical membrane-associated receptors
(see Table S1 for overview on main genomic and non-genomic
signaling properties). The classical estrogen receptors (ERα/β)
(Gundlah et al., 2001; Mitra et al., 2003) and progesterone
receptors (PRA/B) (Brinton et al., 2008) are highly expressed in
brain areas involved in emotion and cognition, such as amyg-
dala and hippocampus. Ovarian hormones can act on multiple
receptor types, such as voltage-gated ion channels, including
GABAA(Gulinello et al., 2001), NMDA (Foy et al., 1999), sero-
tonin (Sumner and Fink, 1998) and dopamine (Becker, 1990)
receptors. While these genomic actions of sex hormones require a
comparably long time—from minutes to hours—and are limited
by the rate of protein biosynthesis, non-genomic modulation of
the membrane receptors is mostly faster and requires only mil-
liseconds to seconds (McEwen, 1991; Cornil et al., 2006). Both
estrogen and progesterone exert acute effects on synaptic phys-
iology through the activation of multiple intracellular signaling
pathways (Minami et al., 1990; Krebs et al., 2000; Wu et al., 2005),
including the MAPK/ERK and the Akt pathway which are both
part to a non-genomic signaling cascade linked to the promotion
of cell survival (Singh, 2001). A distinct progesterone-binding
protein different from the classical PR was identified as a mem-
brane protein, known as 7TMPR, which mediates non-genomic
actions via second-messenger cascades (Zhu et al., 2003a,b).
However, genomic and non-genomic actions of hormones may
also be coupled, so the distinctions are not as clear-cut as was first
thought (Vasudevan and Pfaff, 2008).
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It is noteworthy that most cellular effects of ovarian hormones
have important roles in cell survival, apoptosis, function, and
brain development and may act as critical neuroregulatory, neu-
rotropic, and neuroprotective factors in brain physiology and
pathological conditions of the brain. Effects on structure and
function of the brain have been documented.
EFFECTS ON STRUCTURE
For instance, fairly recent studies have shown that proges-
terone, progestin or progestin metabolites could have the capac-
ity to induce or inhibit neuroplastic changes by preventing
microglia from releasing harmful free radicals (Muller and
Kerschbaum, 2006) or by stimulating myelin production (Baulieu
and Schumacher, 2000). Furthermore, ovarian hormones also
exhibit profound effect on neurotrophins such as brain-derived
neurotrophic factor (BDNF). BDNF has been shown to play a
key role in neuronal survival, in promoting neuronal regener-
ation following injury and regulating neurotransmitter system
(Scharfman and MacLusky, 2006; Sohrabji and Lewis, 2006).
Estrogen treatment seems to increase BDNF expression in sev-
eral brain regions including hippocampus, amygdala and cortex
(Zhou et al., 2005), and has been shown to decrease the risk
for neurodegenerative diseases such as Parkinson’s disease and
Alzheimer’s disease (Sohrabji and Lewis, 2006).
However, much translational work remains to be done, and
it is not clear which of these mechanisms are most relevant to
clinical use. As an example, evidence for the beneficial effects
of progesterone on cognitive outcome following traumatic brain
injury has recently been reviewed as promising (Ma et al., 2012)—
emphasizing the need to further promote this research direction.
Although estrogen and progesterone target multiple regions
in the brain (Brinton et al., 2008), one brain region that has
been the focus of many studies investigating potential neu-
rotropic effects of these hormones is the hippocampus, a brain
region associated with various memory functions (Bliss and
Collingridge, 1993; Adams et al., 2004). Both, acute estro-
gen and progesterone treatment have been shown to increase
synapse density and spine formation in hippocampal structures
in rodents, respectively (Woolley and McEwen, 1993). However,
the generative effects of progesterone seem to disappear after
chronic treatment. Furthermore, progesterone has also been
shown to down-regulate estrogen-induced synapses when added
to estrogen-administration chronically (Woolley and McEwen,
1993). Thus, the duration and combination of ovarian hormone
supplementation seems to be essential for its neuroplastic effects
on brain structures, such as the hippocampus. Therefore, the
overall modulatory effect of ovarian hormones is more complex
than simple mechanistic processes of up- and down-regulation of
expression patterns in isolated brain regions.
In humans, evidence for hormone-dependent modulatory
effects on brain structure stems from hormonal replacement ther-
apy (HRT) studies. The importance of ovarian hormones has lead
to its use as HRT, primarily to treat menopausal/postmenopausal
symptoms such as hot flashes and night sweat. However, struc-
tural and functional changes associated with HRT regimes have
sparked a heightened interest in ovarian hormone effects in
the human body. For instance, brain structure changes due
to HRT seem to be most prominent in the hippocampus.
Women using HRT showed an increased hippocampal vol-
ume compared to men and women who never used HRT
(Lord et al., 2008).
Not only are exogenous sex steroid hormones likely to influ-
ence the structure and function of the hippocampus, but variable
sex steroid levels across the female lifespan have also been asso-
ciated with alterations in hippocampal structure (Adams et al.,
2004; Galea et al., 2008).
EFFECTS ON FUNCTION
Beyond structural changes mediated by HRT, ovarian hormone
supplementation is also known to have prominent effects on
mood and cognitive functioning in domains such as working
memory and executive control. In general, positive (Hogervorst
et al., 2000; LeBlanc et al., 2001; Rice and Morse, 2003; Weber
et al., 2014) and negative (Rapp et al., 2003; Shumaker et al.,
2003) effects on cognition have been reported for HRT. In virtue
of these contradictory findings, HRT is currently much under
debate. However, it seems that timing (MacLennan et al., 2006)
and dose (Rice, 2002) are critical aspects of how the impact of
HRT unfolds.
A woman’s lifespan is characterized by major hormonal transi-
tion periods beginning with rising estrogen level during puberty
(Angold et al., 1998), high estrogen levels during pregnancy
and rapid falls postpartum (Galea et al., 2001), declining lev-
els during perimenopause (Cohen et al., 2006a) and low levels
postmenopausal. Intriguingly, these major shifts in sex hormone
levels seem to be paralleled by the incidence rates of mood
disorders such as unipolar depression (Figure 2). According to
the monoamine hypotheses of depression (Hindmarch, 2002),
depressed mood seems to be accompanied by alternations in
neurotransmitter functioning and transmission. Ovarian hor-
mones are known to exhibit modulatory effects on synaptic
transmission. These modulatory effects can be achieved by alter-
ing the responsiveness of postsynaptic receptors (Yankova et al.,
2001; Maejima et al., 2013) or the presynaptic release of neu-
rotransmitters (Yokomaku et al., 2003). The alternation of both
mechanisms largely affect the neurochemical systems involved
in healthy emotional and cognitive control, such as dopamin-
ergic, serotonergic, glutamatergic and γ-aminobutyric acid
(GABA)-ergic systems.
Along with the major hormonal transition periods, sub-
tle changes in endogenous sex hormones, as occur during the
monthly cycle, have also been associated with changes in mood
(Backstrom et al., 2014). A subgroup of women, however, suffers
from clinical level of premenstrual mood changes called premen-
strual dysphoric disorder (PMDD), a condition that has recently
been included in the DSM-V (Epperson et al., 2012a). PMDD
core symptoms include anxiety, irritability and depressed mood
(Epperson et al., 2012a). As the absolute levels of ovarian hor-
mones do not seem to differ significantly in PMDD women and
healthy controls (Backstrom et al., 2003), one hypothesis pro-
poses that it is a heightened vulnerability of the central nervous
system to normal ovarian function and physiological changes
(Schmidt et al., 1998; Huo et al., 2007) rather than hormone
imbalance, that predisposes women to PMDD. In the pathology
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of PMDD, the normal functioning of predominantly two main
neurotransmitter system, the serotonergic and dopaminergic
system seems to be impaired.
The present review aims to summarize recent findings on the
interaction between ovarian hormones and various neurotrans-
mitter systems in the brain. The second part of the review focuses
on the discussion of these findings in the context of neuropsychi-
atric diseases that display a substantial sexual dimorphism, such
as affective disorders and Alzheimer’s disease.
SEX HORMONES AND THEIR INTERACTIONWITH
NEUROTRANSMITTER SYSTEMS—POTENTIAL
MECHANISMS FOR SEX HORMONES TO EFFECT BRAIN
STRUCTURE AND FUNCTION
The classification of the main neurotransmitter systems are
summarized in Table S1.
SEX HORMONES AND GLUTAMATE INTERACTION
Glutamate acts as the main excitatory neurotransmitter in the
CNS and is a proximal regulator of cognitive domains such as
learning and memory (Gazzaley et al., 1996; Foy et al., 1999;
Riedel et al., 2003). The integration of glutamatergic transmis-
sion is fundamental for normal cognitive functioning and mental
health (Schwartz et al., 2012; Abdallah et al., 2014). The cortical
glutamate projections are organized in descending and ascend-
ing pathways that project throughout much of the telencephalon
(Figure 1A). The impact of ovarian hormones on the gluta-
matergic system has been studied extensively, especially in cell
cultures (Yokomaku et al., 2003) and animal models (Bethea
and Reddy, 2012; Wei et al., 2014). Both stimulatory (Yokomaku
et al., 2003) and inhibitory (Smith et al., 1987a) effects of ovarian
hormones have been reported. In rodents, several mechanisms
through which ovarian hormones may influence glutamatergic
neurotransmission have been proposed: progesterone has been
shown to suppress the excitatory glutamate response in a dose-
dependent fashion (Smith et al., 1987a), while estrogen exhibits
facilitating effects on glutamate transmission (Yokomaku et al.,
2003). A physiological dose of progesterone in ovariectomized
rats has been reported to reduce glutamate-response by 87% via
attenuation of non-NMDA receptors (AMPA, Kainate) (Smith
et al., 1987b). The magnitude of the attenuation seems directly
proportional to the progesterone dose. Whereas progesterone
mainly impacts non-NMDA receptors (Smith et al., 1987a), the
mechanisms underlying estrogen effects on cognition are related
to NMDA glutamate receptors. Estrogen has been shown to pro-
mote an increase in NMDA receptor subunit expression (Gazzaley
et al., 1996; Adams et al., 2004), binding sites (Woolley et al.,
1997) and neuronal sensitivity to synaptic input mediated by
NMDA glutamate receptors (Rudick and Woolley, 2001; Smith
and Woolley, 2004). The blockade of NMDA receptors with
antagonists attenuates the effects of estrogen on neuronal corre-
lates of memory, such as long-term potentiation (LTP) (Brinton
et al., 1997; Foy et al., 1999). Moreover, estrogen facilitates the
spine-maturation process (Hao et al., 2006). A plethora of animal
studies have shown that estrogen with and without progesterone
increases dendritic spines through the up-regulation of AMPA
(Liu et al., 2008; Kramar et al., 2009) and NMDA receptors
(Woolley et al., 1997) in the hippocampus and prefrontal cortex
(PFC) (Hao et al., 2006). In addition, ovariectomy reduced synap-
tic markers in these regions (Gould et al., 1990; Hao et al.,
2006).
Beside ovarian influence on spine density, precursors for pro-
gesterone (such as pregnenolone) seem to have complex effects
on glutamate release itself that depends on the developmental
period, brain region and functional state (Zheng, 2009): in the
hippocampus (Meyer et al., 2002) and in the prefrontal cortex
(Dong et al., 2005), which are brain regions of high relevance
to memory and executive control, progesterone precursors have
been shown to impact spontaneous glutamate release that may
contribute to the maturation and/or maintenance of synapses.
The latter might point toward the well-established neuroprotec-
tive effects (Mattson et al., 1997; Wang et al., 2001) of ovarian
hormones from insults such as oxidative stress and glutamate
excitotoxicity.
In addition to these cellular effects, recent studies report that
the interaction between estrogen and glutamate can affect cog-
nitive domains such as working memory and executive function
under harmful conditions. Brain regions hypothesized to underlie
these cognitive domains—such as the PFC and hippocampus—
seem largely dependent on normal estrogen signaling to counter
insults such as stress: In a repeated stress paradigm, Wei et al.
(2014) found a beneficial effect of endogenous estrogen on glu-
tamate receptors in the PFC in female rats compared to male rats.
The authors propose that detrimental effects of repeated stress are
present in females when estrogen signaling is blocked, whereas
detrimental effects are blocked in males when estrogen signal-
ing is activated. In particular, blocking estrogen synthesis enzyme
aromatase with formestane in PFC revealed stress-induced glu-
tamatergic deficits and memory impairment in female rats (Wei
et al., 2014). Thus, these results suggest that the female rodent
PFC has an endogenous capacity to generate estrogen that pro-
vides protection against subchronic repeated stress. How gen-
der differences in response to stressors are modulated by hor-
monal status is extensively reviewed by Cohen and Yehuda
(2011). In addition to endogenous estrogen levels, also exogenous
administered estrogen seems to increase the resilience to stress
and preserve hippocampal functioning in rats (Bredemann and
McMahon, 2014).
Although animal studies assessing electrophysiological, bio-
chemical and behavioral markers for sex hormonal impacts on
the glutamatergic system provide useful insights on underlying
mechanisms, extrapolation to humans is difficult. Some of the
beneficial effects of estrogen on cognitive function have also been
shown in humans: premenopausal women who were treated with
a gonadotropin releasing hormone analog which chemically sup-
pressed ovarian function experienced significant deterioration of
mood and worsening of performance in working memory tasks
(Grigorova et al., 2006). In this study, the estrogen levels dropped
to postmenopausal values implicating that low endogenous levels
of estrogen might impair normal cognitive functioning.
Although this study report positive effects of estrogen on
working memory and executive function, the results are incon-
clusive (Grigorova and Sherwin, 2006), and the advisability of
hormonal replacement is still much under debate. However, a
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FIGURE 1 | Schematic representation of the main human central
glutamatergic system (A, purple), GABAergic system (B, green),
dopaminergic system (C, blue) and serotonergic system (D, orange)
including a schematic display of estrogen (ERα and ERβ combined)
and progesterone receptor distribution in the human brain. No
distinction is made between ERα and ERβ sub-specification for this
schematic display, however the localization for those subtypes can differ
[e.g., so far no evidence could be gathered supporting ERα expression in
the dorsal raphe nucleus (DRN) (Sugiyama et al., 2010)], however there
have been reports on ERβ expression in primate DRN in the midbrain
(Gundlah et al., 2001; Sugiyama et al., 2010). Estrogen (red triangles)
receptors are predominantly present in cerebellum, VTA, hippocampus,
amygdala, and frontal cortex; as well as in the raphe nuclei of the midbrain
(Gundlah et al., 2001; Osterlund and Hurd, 2001; Mitra et al., 2003; Perlman
et al., 2005; Sugiyama et al., 2010). Progesterone (filled circles) receptor
expression could be shown in the amygdala, midbrain, brain stem,
hippocampus, cerebellum and frontal cortex with no apparent restrictions
to specific cell types (Bethea, 1993; Gundlah et al., 2001). (A) The cortical
glutamatergic projections can be separated in five main pathways (Schwartz
et al., 2012): (1) from prefrontal to brainstem areas (dorsal/medial raphe,
VTA, substantia nigra); (2) from prefrontal cortex to striatum and nucleus
accumbens; (3) the thalamocortical pathway, from thalamus to cortical
pyramidal neurons; (4) inverse projections from cortex to thalamus; and (5)
intra-cortical glutamate projections. (B) GABAergic projections are widely
distributed throughout the brain. Main projections can be found originating
in the striatum to the substantia nigra and the brain stem. Further
projections innervate the thalamus from the substantia nigra (Fino and
Venance, 2010). Moreover, GABAergic projections originate from (1)
hypothalamus to occipital cortex and parietal cortex; (2) from hippocampus
to thalamus and striatum, and (3) from nucleus accumbens to thalamus.
The cerebellum is also highly innervated by GABAergic projections. (C) The
cortical dopaminergic pathways build four distinct pathways (Felten and
Shetty, 2010): (1) the mesolimbic pathway; with projections from VTA to
limbic structures, such as the nucleus accumbens, hippocampus, amygdala
and prefrontal cortex, (2) the mesocortical pathway; with projections from
the VTA to cerebral cortex, (3) the nigrostriatal pathway; with connections
between substantia nigra and striatum, (4) the tuberoinfundibular pathway;
with projections starting from the hypothalamus to the pituitary gland. (D)
The majority of serotonergic projections originates from the dorsal and
median raphe nuclei, innervating the amygdala, hypothalamus, thalamus,
striatum, cerebral cortex and hippocampus (Felten and Shetty, 2010): (1)
The medial raphe predominantly projects to the frontal cortex and the
hippocampus (Hornung, 2003) and (2) the areas of the dorsal raphe mainly
innervate the thalamus, striatum and cerebral cortex (Geyer et al., 1976).
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large number of studies with behavioral testing during hormonal
transitions, such as the menstrual cycle or postmenopause,
point toward an estrogen-dependent improvement in memory
(Epperson et al., 2012b; Hampson and Morley, 2013), but the
neurochemical pathways underlying these changes remain to be
identified. A useful approach to assess glutamate release in vivo
in humans might be a pharmacological stimulation of the glu-
tamatergic system with positron emission tomography (PET)
using a glutamate-receptor radioligand. In conjuction with MR-
Imaging it could link glutamate release to brain activation during,
i.e., working memory tasks. Such methods should lead to a bet-
ter understanding of the interaction between sex hormones and
glutamatergic neurotransmission.
SEX STEROID HORMONE AND GAMMA-AMINOBUTYRIC-ACID
INTERACTION
Gamma-aminobutyric acid (GABA) is the most abundant and
widely distributed inhibitory neurotransmitter in the CNS
(Sieghart and Sperk, 2002; Marshall, 2008). GABAergic neuro-
transmission through interneurons is known to modulate local
neuronal circuits via, for example, activation of dopaminergic
(Dewey et al., 1992) and serotonergic neurons (Andrade et al.,
1986). GABAergic interneurons can be differentiated into two
types, each acting via its receptor-subtype (Table S2). GABA
receptors are highly distributed in cortical, hippocampal, thala-
mic, basal ganglia and cerebellar structures (Figure 1B).
GABAA receptors mediate major inhibitory GABAergic
actions in the CNS and are putative sites for ovarian hormone
effects (Backstrom et al., 2011, 2014). Whereas estrogen seems to
suppress GABA inhibitory input (Murphy et al., 1998a), proges-
terone and its neuroactive metabolites (allopregnanolone, preg-
nanolone) seem to facilitate GABAergic transmission through
their action at GABAA receptors (van Wingen et al., 2008;
Deligiannidis et al., 2013). Particularly, allopregnanolone acts like
a positive modulator and potentiates the inhibitory action of
GABA by increasing channel openings of the GABA-gated chlo-
ride channels (Rupprecht, 1997) and augmenting other inhibitory
neuronal responses to GABA (Smith, 1991). This facilitation of
GABA-mediated Cl− current can result in inhibitory effects on
neuronal function.
The interaction of progesterone and its neurosteroids with
neuronal GABAA receptors is significantly influenced by the
subunit composition of the receptor, local metabolism and phos-
phorylation (Belelli et al., 2006; Backstrom et al., 2014). Especially
the subunit composition seems to play a crucial role in inhibitory
neurotransmission and its effects on a larger scale such as mood
and cognition (Backstrom et al., 2014). Animal studies indicate
a relationship between changes in α4 and δ subunits of GABAA
receptors and anxiogenic effects of allopregnanolone (Gulinello
et al., 2001). Alternations in both GABA receptor subunit expres-
sion and anxiety behavior reflect a complex temporal pattern
following sustained exposure to progesterone metabolites: An
increase in hippocampal expression of the α4 subunit is seen to
correlate with increased anxiety after 48 h exposure to allopreg-
nanolone (Hsu et al., 2003). Paradoxically, in high concentrations,
progesterone and its neurosteroids are also known to be anxi-
olytic, sedative, and antiepileptic, both in animals and humans
(Backstrom et al., 2014). Allopregnanolone naturally fluctuates
across the female menstrual cycle, with its highest concentra-
tion in the luteal phase when progesterone is high and estrogen
is low (Backstrom et al., 2014). In women with PMDD, proges-
terone withdrawal associated with allopregnanolone increase in
the luteal phase has been linked to changes in mood (Epperson
et al., 2012a). As absolute levels of ovarian hormones do not
seem to differ in PMDD women compared to healthy controls
(Backstrom et al., 2003), it is proposed that a heightened vulner-
ability of the central nervous system to normal ovarian function
predisposes women to PMDD.
Beyond its influence on mood, progesterone and its metabo-
lites also seem to impact the memory and learning domains.
Animal studies could show that allopregnanolone can inhibit
neural activity in the CA1 and the dental gyrus area of the
hippocampus (Landgren et al., 1998). The magnitude of the allo-
pregnanolone inhibition is dependent on the phase of the rodent
estrus cycle, with its maximum in the luteal phase. In humans,
acute progesterone or allopregnanolone administration has been
shown to impair face recognition and episodic memory in healthy
women, while endogenous allopregnanolone level does not seem
to impact their memory and learning. However, women suf-
fering from PMDD showed impaired working memory in N2
and N3 back tasks during their symptomatic phase (Yen et al.,
2012). Thus, healthy women seems to show memory impair-
ments when progesterone and its metabolites are administered
exogenously, while women with PMDD are more vulnerable to
endogenous fluctuations of progesterone and allopregnanolone
across the menstrual cycle.
Based on all these findings, Backstrom and colleagues recently
hypothesized that an increase of the α4, β, δ subunit compo-
sition, together with a heightened vulnerability toward elevated
allopregnanolone levels, could be key factors in the progesterone
withdrawal model of PMDD (Backstrom et al., 2014). As PMDD
heightens the risk for other kinds of depression, such as post-
partum depression, a detailed understanding of the underlying
mechanisms of PMDD might foster therapeutic approaches and
thereby subsequently promote female mental health.
SEX STEROID HORMONE AND DOPAMINE INTERACTION
Dopamine (DA) is a key neurotransmitter that is implicated in
motor control (Sealfon and Olanow, 2000; Dluzen and Horstink,
2003), learning (Daniel et al., 2006), motivation (Becker, 2009),
reward (Hikosaka et al., 2014), decision-making and work-
ing memory (Jacobs and D’Esposito, 2011; Uban et al., 2012).
Brain areas that show rich dopaminergic innervation include
the striatum, substantia nigra and hypothalamus (Sealfon and
Olanow, 2000); typically four main pathways are described for the
dopaminergic system (Figure 1C).
Sex hormones can impact dopaminergic neurotransmission
via a multitude of mechanisms (synthesis, release, turnover and
degradation, pre-and postsynaptic receptors, transporters, for
details see Table S2). Stimulating (Becker, 1990, 2000; Thompson
and Moss, 1994; Becker and Hu, 2008), as well as inhibiting
(Disshon et al., 1998; Watson et al., 2006; Morel et al., 2009)
effects of estrogen on dopaminergic neurotransmission have been
documented. These conflicting findings are not surprising when
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considering the many aspects that can influence the impact of
estrogen on the DA-system such as dose and time of testing, mode
of administration, duration of exposure, and time after exposure
(Di Paolo, 1994). Most experts agree that estrogen has an overall
facilitating effect on dopaminergic neurotransmission (Sanchez
et al., 2010; Jacobs and D’Esposito, 2011; Uban et al., 2012;
Rey et al., 2014). For progesterone-modulating effects, it seems
that, in addition to the previously mentioned aspects, priming
with estrogen can also influence the impact of progesterone on
dopaminergic transmission: in vitro (Dluzen and Ramirez, 1984;
Cabrera et al., 1993) and in vivo (Becker, 1990) experiments
support a stimulating effect on DA-release when rats where pre-
exposed to estrogen whereas no such effects could be observed in
non-estrogen treated rats.
Still much work remains to be done to improve our under-
standing of how these findings translate to the human brain,
and ultimately link to human behavior and potentially pathol-
ogy. Nevertheless, there are several examples for recent evi-
dence converging from animal and human work that emphasize
the relevance of this line of research to female mental health.
Recent studies report on the interaction between estrogen and
dopamine on cognitive domains, such as decision-making (Uban
et al., 2012), fear extinction (Rey et al., 2014) and memory bias
(Quinlan et al., 2013). The authors conclude that estradiol biases
decision-making toward smaller, more accessible rewards (Uban
et al., 2012), that a low-estrogen state during fear extinction is
detrimental for an optimal freezing suppression after extinction,
which is mediated by D1-receptor signaling (Rey et al., 2014)
and that memory bias is mediated by the interaction of estra-
diol and dopamine in the dorsal striatum (Quinlan et al., 2013).
In particular, the latter two studies argue that the effect of estro-
gen depends on individual variation in baseline DA function and
endorse the concept of estrogen-dopamine interactions to mirror
an inverted U-shaped curve, a model that has also been tested by
several other studies (Williams andGoldman-Rakic, 1995; Gjedde
et al., 2010). Thus, optimal signaling may depend on the levels of
estrogen to best interact with dopamine levels in themedian range
for optimal striatal function and optimal performance during
such a task.
This hypothesis has been tested in humans. Estrogen-DA
interaction in PFC function during a working memory task
has been linked to variations in the gene for catechol-o-
methyltransferase (COMT), the enzyme that metabolizes synap-
tic dopamine (Jacobs and D’Esposito, 2011). The authors found
val/val women to perform poorly with low estrogen levels (early
follicular phase) and improve with rising estrogen levels (late
follicular phase), whereasmet/met women show the opposite pat-
tern. Best performers were women with high COMT (low DA)
just prior to ovulation (high estrogen levels), and women with
low COMT activity (high DA) during menses, further support-
ing the inverted U-shaped action of DA. Based on these findings,
the authors propose that the effect of estrogen on cognitive per-
formance could be either beneficial or detrimental depending
on COMT genotype and COMT enzymatic activity (Jacobs and
D’Esposito, 2011). While these concepts require further testing,
they offer interesting perspectives for the planning of HRT in
postmenopausal women.
Several neuropsychiatric pathologies that display a substantial
sexual dimorphism have been linked to abnormal dopamin-
ergic function, such as schizophrenia (Brunelin et al., 2013),
Parkinson’s (Dluzen and Horstink, 2003; Horstink et al., 2003;
Sanchez et al., 2010) or Alzheimer’s disease (Reeves et al., 2009).
Thus, a better understanding of the interaction between sex
hormones and dopaminergic neurotransmission could help to
improve pharmacological treatment regimens for these diseases
and significantly impact women’s mental health.
SEX HORMONES AND SEROTONIN INTERACTION
The serotonergic system serves a multitude of roles, most promi-
nently balancingmood (Martinowich and Lu, 2008). Several sero-
tonergically mediated physiological functions are tightly linked
to steroid hormones such as sexual behavior or stress response
(Biegon, 1990). The highest expression of serotonergic neu-
rons can be found in the dorsal and medial raphe nuclei of
the midbrain with ascending fibers projecting to frontal cor-
tex, striatum, thalamus, amygdala, hypothalamus and hippocam-
pus (Figure 1D). Serotonin (5-HT) receptor subtypes belong to
G-protein coupled or ligand-gated ion channels and 15 different
subtypes have been characterized (Table S2), which is why disen-
tangling specific neurochemical action for each subtype has been
described as complex (Murphy et al., 1998b).
It is also difficult to provide a detailed characterization of sero-
tonergic action in the CNS and how it can be influenced by sex
hormones. A multitude of factors plays into serotonergic neu-
rotransmission such as: endogenous levels of serotonin, more
than 15 neuroreceptor-subtypes, individual receptor expression,
binding and affinity, the functional polymorphism of the sero-
tonin transporter (5-HTT), intracellular protein levels, synthetic
enzymes, and the prominent sexual dimorphism (Rubinow et al.,
1998). The 5-HTT transports 5-HT back from the synaptic cleft
into the presynaptic neuron, where the neurotransmitter is pre-
dominantly metabolized by Monoamine Oxidase A (MAO-A).
Furthermore, the serotonergic system is a main target of steroid
hormones, cytokines, neuropeptides and trophic factors, all of
which impact the generation and efficacy of serotonergic neuro-
transmission (McEwen, 2002; Bethea and Reddy, 2012).
Estrogen has been reported to have potent serotonin-
modulating properties from the level of neurotransmitter synthe-
sis via the regulation of tryptophan hydroxylase (Lu et al., 1999)
and degradation of 5-HT to the density and binding of 5-HT
receptors (Bethea et al., 2002). The effect of estrogen on serotonin
expression seems to depend on several factors such as: receptor
subtype, brain area and in case of estrogen treatment also on the
duration of treatment. On the one hand, estrogen administration
has been found to increase tryptophan hydroxylase mRNA (TPH,
serotonin synthesizing enzyme) (Pecins-Thompson et al., 1996;
Berman et al., 2006); 5-HT2A mRNA levels in brain areas relevant
for the control of mood, mental state and cognition (Sumner and
Fink, 1998) and 5-HTT mRNA when administered for a longer
period (Smith et al., 2004). On the other hand, estrogen treatment
has also been observed to decrease mRNA related to serotonergic
neurotransmission. For instance, 5-HT1B autoreceptor mRNA in
dorsal raphe (Hiroi and Neumaier, 2009) and MAO-A mRNA
and activity (Gundlah et al., 2002) are decreased after estrogen
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treatment. Furthermore, acute estrogen administration decreases
5-HTTmRNA levels (Pecins-Thompson et al., 1998) and 5-HT1A
mRNA levels and binding. The latter effect disappears after a
more chronic treatment-regimen (Osterlund et al., 1999, 2000).
Thus, assigning the effects of estrogen on serotonin to a homoge-
nous functional class of stimulation or inhibition seems not to be
feasible.
Progesterone has been suggested to increase serotonergic neu-
rotransmission via the regulation of the expression of serotonin-
related genes and proteins (Bethea et al., 2002; Smith et al., 2004;
Sanchez et al., 2005). Chronic progesterone treatment seems to
decrease 5-HT1A receptor expression in rats (Biegon et al., 1983),
a finding that has also been reported for progesterone in com-
bination with estrogen (Henderson and Bethea, 2008). In this
study, the authors showed a decrease of 5HT2C receptor expres-
sion when progesterone was added to the estrogen administration
in macaques (Henderson and Bethea, 2008).
Both, estrogen and progesterone have been demonstrated to
modify the serotonergic responsivity to selective serotonin reup-
take inhibitors (SSRI)-administration (Benmansour et al., 2012).
Experiments in rhesus macaques suggest that the sex steroids
interact with the functional polymorphism of the 5-HTT to
influence SSRI treatment response (Michopoulos et al., 2011).
In humans, a recent study found an association between func-
tional polymorphic region of the serotonin transporter gene
(5-HTTLPR) and antidepressant efficacy in non-menopausal
women (Gressier et al., 2014). Non-menopausal women with
at least one copy of the long allele showed better antidepres-
sant efficacy than those who were homozygous for the short
allele (Gressier et al., 2014). Intriguingly, no differences were
found in menopausal women. Menopause is typically associated
with estrogen withdrawal suggesting that the hormonal status is
critical for antidepressant efficacy. These findings add to previ-
ous studies suggesting that menopausal women gain less benefit
from antidepressant treatments compared to women during their
reproductive years (Pinto-Meza et al., 2006; Pae et al., 2009).
In conclusion, the interaction between ovarian hormone levels,
age and genotype appear to modulate serotonergic reactivity in
females.
INFLUENCE OF SEX STEROID HORMONES ON NEURAL
CIRCUITS: FROM HEALTH TO VULNERABILITY AND DISEASE
THE IMPACT OF SEX HORMONE FLUCTUATION ON THE HEALTHY
BRAIN
Several lines of evidence from neuroimaging indicate modulatory
effects of sex steroid hormones on different structural and func-
tional brain connectivity parameters such as white matter struc-
ture (De Bondt et al., 2013), gray matter structure (Protopopescu
et al., 2008), and overall network connectivity (Hausmann et al.,
2002; Weis et al., 2008; Weis and Hausmann, 2010; Thimm et al.,
2014).
On the overall brain level, it has been proposed that ovarian
hormones facilitate both cortico-cortical and subcortico-cortical
functional connectivity, whereas testosterone seems to decrease
subcortico-cortical functional connectivity, but increases func-
tional connectivity between subcortical brain areas, as reviewed
by Peper et al. (2011). In line with this hypothesis, high levels
of endogenous estradiol and progesterone have been observed
to raise functional communication between both hemispheres
(Hausmann et al., 2002), a mechanism that has been speculated to
underlie sex differences in functional cerebral asymmetries (FCA)
(Hausmann et al., 2002; Weis and Hausmann, 2010).
Ovarian hormone levels fluctuate on a monthly basis in
women. Thus, studying functional and structural brain organi-
zation across the menstrual cycle represents a feasible approach
to address the question whether sex hormones can influence
functional and structural connectivity. A voxel-based morphom-
etry (VBM) MRI study found gray matter density to increase in
the right anterior hippocampus and decrease in the right dorsal
basal ganglia in the late-follicular phase compared to late luteal
phase (Protopopescu et al., 2008). Pletzer et al. report signifi-
cant differences in gray matter density between naturally cycling
women and women using oral contraceptives (OC), observ-
ing increased gray matter volume in prefrontal and temporal
regions in OC users (Pletzer et al., 2010). Furthermore, the poten-
tial impact of hormonal contraception on brain structure does
not seem to be limited to gray matter, and white matter tracts
seem to be altered by OC use as well, especially in the fornix
(De Bondt et al., 2013).
Sexual dimorphism in functional networks of the brain, such
as the default mode network (DMN), a network that is proposed
to underlie physiological processes unrelated to any particular
thought (Gusnard et al., 2001), has been well established (Peper
et al., 2011; Tian et al., 2011). However, few neuroimaging studies
have investigated the extent to which sex hormones can influ-
ence the behavior of functional networks at rest. A recent study
exploring functional connectivity of the anterior DMN and the
executive control network (ECN) found differences in intrinsic
connectivity between OC users and naturally cycling women, and
it reported connectivity to differ most between groups in the left
angular gyrus, themiddle frontal gyrus, and the anterior cingulate
cortex (ACC) (Petersen et al., 2013). Within the group of natu-
rally cycling women, the follicular phase was associated with an
increase in connectivity with the ECN relative to the luteal phase
in the right ACC (Petersen et al., 2013).
A better understanding of functional and structural connectiv-
ity changes in the context of sex steroid fluctuations seems crucial
to establish neurobiological models of neuropsychiatric diseases
that display a strong sexual dimorphism, such as depression
(Kessler et al., 1993; Kessler, 2003). Linking functional connec-
tivity measures to neurochemical mechanisms during hormonal
transition periods can be viewed as one of the next frontiers in the
field of neuroimaging.
HOW SEX HORMONE FLUCTUATION CAN REPRESENT A PERIOD OF
HEIGHTENED RISK FOR THE BRAIN: FROM VULNERABILITY TO
DISEASE
Women have a lifetime prevalence rate for depression 1.5–3 times
higher than men (Kessler, 2003). This distinction between the
sexes is most prominent during the reproductive years (Soares
and Zitek, 2008). For women, hormonal transitions across their
lifespan represent periods of elevated vulnerability to develop-
ment of mood disorders: elevated and fluctuating sex hormones
seem to predispose women to mood-disturbance, beginning with
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a heightened risk of developing a depressive episode following
puberty (Soares and Zitek, 2008).
Pregnancy has been speculated to offer some protection
against depression (Ko et al., 2012), including findings of lower
suicide rates during pregnancy (Hawton, 2000; Oates, 2003).
However, other work suggests that there is no difference in
the prevalence rates of depression between pregnant and non-
pregnant women (Vesga-Lopez et al., 2008). In a recent extensive
study that screened 10,000 postpartum women, one third of
screen-positive postpartum depressed women reported the onset
of their depressive symptoms during pregnancy (Wisner et al.,
2013). Pregnancy has also been discussed to confer vulnerability
upon women who are already at risk of developing a depressive
illness (Cohen et al., 2004, 2006b). Furthermore, recent findings
(Rallis et al., 2014) indicate that symptom levels of depression,
anxiety, and stress vary over the course of pregnancy, with women
experiencing fewer symptoms during the middle of the preg-
nancy. Increased depressions scores early in pregnancy seemed to
be predictive of later depression symptoms, especially postbirth
(Rallis et al., 2014).
In summary, the current evidence does not unequivocally sup-
port pregnancy itself to pose an increased risk of developing
depression, nor does it clearly identify this period as protection
for the majority of women from mood disorders. Factors that
might contribute to this ambiguity include that clinical assess-
ment of depression during pregnancy and the postpartum period
is complicated, because many of the typical depressive symptoms
(disruption of sleep and appetite) are unavoidable during preg-
nancy and postpartum (Marcus, 2009), and that there may be
a distinct pattern of reactivity in women who have never had
a depressive episode before, vs. women who are already at risk
(Cohen et al., 2004, 2006b).
To better address these challenges in the future, several strate-
gies could be implemented: (1) A routine and serial screen-
ing process for depressive symptoms, administered by trained
midwives, throughout pregnancy, and during the immedi-
ate and the extended postpartum period that focuses on the
psychological symptoms, such as changes in mood, the ten-
dency to ruminate, and anxiety. Studies suggest that screening
with simple checklists and short screening tools, such as the
Edinburgh Depression Scale, can already result in highly effi-
cient screening for postpartum depression (PPD) (MacArthur
et al., 2002). (2) Standardized psychoeducation on depres-
sion during pregnancy, postpartum blues, and PPD needs to
become an integral part of standardized prenatal and post-
partum care to help destigmatize PPD and facilitate the pro-
cess of seeking proper diagnosis and adequate treatment. (3)
Based on converging data from 17,000 women, individually
tailored psychosocial and psychological intervention is a very
promising way to prevent PPD, with provision of intensive,
professionally-based postpartum home visits, telephone-based
peer support, and interpersonal psychotherapy among the most
effective strategies (Dennis and Dowswell, 2013). Thus, within
the psychoeducational process, emphasis should be placed on
individual risk evaluation, as well as on the wide range of
intervention options available to women who fall within the
spectrum of pregnancy-related or postpartum mood disorders,
covering aspects from psychosocial support, psychotherapy, and
psychopharmacology.
In this section, we focus on three examples of hormonal
transition across the adult female lifespan: (a) the postpartum
period, (b) the perimenopausal period, and (c) the more subtle
fluctuation of sex hormones during the menstrual cycle.
Postpartum period
With the loss of the placenta, estrogen levels decrease 100–1000-
fold during a period of a few days (Nott et al., 1976; O’Hara
and Swain, 1996; O’Hara et al., 2000). This dramatic hormonal
change is likely to induce a cascade of signaling that also affects the
brain. A PET study investigating the neurochemistry of the female
brain in the immediate postpartum period found a substantial
whole-brain increase in MAO-A in the brain in the first week
postpartum compared to womenwho had not recently been preg-
nant (Sacher et al., 2010). MAO-A is an enzyme that metabolizes
monoamines, such as serotonin, dopamine and noradrenaline.
A significant increase in MAO-A has been proposed to be pre-
dictive for the recurrence of major depressive disorder (Meyer
et al., 2006). These findings in humans are in line with the inverse
relationship between estrogen levels and MAO-A which has been
observed in cell lines (Ma et al., 1995), as well as in rat (Luine and
McEwen, 1977; Chevillard et al., 1981) and macaque (Gundlah
et al., 2002; Smith et al., 2004) models. The acute estrogen drop
within the first week postpartum has been proposed to trigger the
subsequent MAO-A peak that could explain the depressed mood
that a majority of mothers experience during this time (Sacher
et al., 2010). Elevated MAO-A levels have also been found in pre-
frontal cortical regions and areas of the ACC in women with PPD
and in women who do not meet criteria for a full PPD but report
postpartum crying (Sacher et al., 2014). Thus, the interaction
between estrogen and MAO-A seems to be a crucial factor in bal-
ancing postpartum mood. Given the current lack of prevention
strategies for PPD, translation of biological concepts to facilitate
the normalization of MAO-A levels in the brain, including poten-
tially attenuating the acute hormonal withdrawal that can precede
such an MAO-elevation, represents a promising line of research.
Further evidence that monoaminergic imbalance contributes
to the development and/or severity of PPD symptomatology
stems from neurochemical investigations of the serotonergic and
the dopaminergic system: similar to depressed patients, PPD-
patients with a history of non-postpartum depressed episodes
seem to display a decrease in 5-HT1A receptors in the ante-
rior cingulate and mesiotemporal cortices (Moses-Kolko et al.,
2012). Postpartum status and unipolar depression have also been
associated with lower striatal D2/3 receptor binding in postpar-
tum and unipolar depressed women compared to healthy women
who were not postpartum (Moses-Kolko et al., 2012). In sum-
mary, the postpartum period seems to be characterized by several
monoaminergic alteration processes that are highly relevant to the
regulation of mood and emotional processing.
GABA has also been implicated in the neurobiology of PPD:
In a human pilot study, reduced occipital cortex GABA levels
have been reported in parallel with decreased allopregnanolone
levels during the postpartum period, irrespective of PPD diag-
nosis (Epperson et al., 2006). In animal models of postpartum
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depression, abnormalities of GABA receptors (R delta and gamma
2 subunits) have been observed and discussed as being related to
the substantial progesterone decline postpartum (Maguire and
Mody, 2008). Further work in animal models mimicking the
hormonal environment of the postpartum period revealed a char-
acteristic behavioral phenotype with vulnerability to helplessness,
increased anxiety, and aggression that has been associated with
differences in expression of several key genes, such as 5-HTT,
BDNF, GABA-A receptor type 4 (Suda et al., 2008). Data obtained
from elegant animal models for PPD based on estrogen with-
drawal across parturition (Galea et al., 2001) and exposure to high
cortisol levels (Brummelte et al., 2006) support changes in steroid
hormonal environment to spark dramatic effects in spatial mem-
ory and hippocampal morphology. This work further strengthens
the strong argument that can be made for the heightened plastic-
ity of the postpartum brain that seems to be driven by a closely
intertwined action between sex hormones and neurotransmitters.
Perimenopausal transition
The perimenopausal transition period marks the end of the
reproductive years and is commonly defined as a decline of
ovarian function based on reproductive endocrine and men-
strual cycle changes (Harlow et al., 2003). Three key mark-
ers for the onset of perimenopause are: (1) 7-day or more
change in the menstrual cycle length; (2) a change in men-
strual flow amount or duration, or (3) amenorrhea lasting at
least 3 months (Harlow et al., 2003). Moreover, especially the
increase in FSH levels beside elevated LH levels seems to be
linked to a decline in ovarian function (Harlow et al., 2003).
With the loss of ovarian function and the associated fundamen-
tal changes in the hormonal environment, it is not surprising that
this phase in a woman’s life is accompanied by changes in eating
(Hirschberg, 2012), metabolism (Wing et al., 1991; Lovejoy et al.,
2008), sleep (Guidozzi, 2013), behavior (Copeland et al., 2006),
mood (Cohen et al., 2006a), sexuality (Dennerstein et al., 2003),
immune response (Gameiro et al., 2010), and cognitive function
(Greendale et al., 2012).
The concept that the perimenopausal phase represents a vul-
nerability period for developing a depressive illness is supported
by evidence for a high rate of new-onsetmajor depressive episodes
(MDE) during this time (Cohen et al., 2006a; Freeman et al.,
2006). In a longitudinal, prospective cohort study, Cohen and
colleagues found that women with no lifetime history of depres-
sion who enter the menopausal transition earlier have a sig-
nificant risk of first onset of depression (Cohen et al., 2006a).
Strikingly, women with a previous history of depression, who also
reported the use of antidepressants, had nearly 3 times higher
risk of an earlier perimenopausal transition compared to non-
depressed women (Harlow et al., 2003). Thus, there seems to be
an inverse relationship between depression and the inception of
perimenopause. Early perimenopause increases the risk of severe
mood disturbances, while a lifetime history of depression predis-
poses women to an early onset of perimenopause. Furthermore,
studies by Young et al. and Harlow et al. indicate that depressed
women have lower estradiol and higher LH and FSH level than
non-depressed controls (Young et al., 2000; Harlow et al., 2003).
Whether the decline in estrogen levels or the cyclic fluctuation of
estradiol level, which may increase in the menopausal transition
(Cramer et al., 2002), contribute to the occurrence of depressed
mood remain controversial (Joffe and Cohen, 1998; Halbreich,
2000).
Similar to the postpartum estrogen drop, perimenopausal
estrogen decline seems to relate to an up-regulation of MAO-A
levels in the brain. Rekkas et al. have recently shown greater
MAO-A binding in the prefrontal cortex during the per-
imenopausal transition phase compared with age-matched
women during their reproductive years and during menopause
(Rekkas et al., 2014). The authors did not find any association
between MAO-A binding and physical criteria of perimenopause,
such as menstrual cycle length, vasomotor symptoms or plasma
follicle-stimulating hormone levels. They did, however, find a sig-
nificant correlation betweenMAO-A binding and the tendency to
cry (Rekkas et al., 2014), a psychological symptom that has been
found as a subclinical phenomenon to occur during major shifts
of sex hormonal environment (Sacher et al., 2010; Dowlati et al.,
2014).
Depressive mood during the perimenopausal years may also
be of particular relevance for the development of dementia given
that depressive episodes have been shown to increase the risk
of Alzheimer’s disease in later life (Devanand et al., 1996) and
that severity of depression has been observed to predict pro-
gression from mild cognitive impairment to Alzheimer’s disease
(Van der Mussele et al., 2014) and cognitive function in patients
with central nervous system disease (van Reekum et al., 2000).
Estrogen fluctuations during the perimenopausal phase have been
discussed to influence mood and cognition via several mecha-
nisms. In addition to promoting anti-oxidative states that can
support cell survival, for instance via balancing MAO-A lev-
els (Ou et al., 2006; Fitzgerald et al., 2007), estrogen has been
reported to trigger increased 5-HT2A receptor binding that has
been speculated to reduce the amount of β-amyloid deposition,
a marker for Alzheimer pathology (Nitsch et al., 1994). Thus, it
could be hypothesized that the perimenopausal drop in estrogen
decreases the beneficial effect of increased serotonin binding on
β-amyloid deposition. In ovariectomized rats, acute administra-
tion of estradiol seems to have an antidepressant effect via slowing
extracellular serotonin clearance involving ERβ and G-protein
coupled receptor. Beyond this, estrogen can also block the effect
of SSRIs at the 5-HTT via estrogen receptor alpha (Benmansour
et al., 2012).
Until today, it has been an area of much debate whether
women with depressive symptoms should be treated with HRT,
antidepressants or both. Core menopausal symptoms are related
to deficits in declarative memory (Woods et al., 2000), fine
motor coordination (Bayer and Hausmann, 2010), and feelings
of depression (Hay et al., 1994; Freeman et al., 2006) and anx-
iety (Kessler, 2003; Faravelli et al., 2013; Soares, 2014). Several
reviews and meta-analysis suggest small positive effects of HRT
on verbal memory, attention, and reasoning (Hogervorst et al.,
2000; LeBlanc et al., 2001; Rice and Morse, 2003; Weber et al.,
2014). To generate a positive effect on cognition, the age of
HRT onset seems to be crucial. Women receiving HRT earlier
seem to improve their cognitive performance compared to either
older HRT-treated women or untreated women (MacLennan
www.frontiersin.org February 2015 | Volume 9 | Article 37 | 9
Barth et al. Interactions between sex hormones and neurotransmitters
et al., 2006). This report is supported by neuroimaging find-
ings suggesting increases in hippocampal size following estrogen
treatment in postmenopausal women (Eberling et al., 2003).
Animal studies further emphasize the age-related effects of estro-
gen treatment: Adams and colleagues report an up-regulation
of both NMDA receptors and dendritic spines on CA1 pyra-
midal neurons in the hippocampus of young adult female rats,
while aging rats respond to estrogen with the up-regulation
of the NMDA receptor R1 subunit expression, solely (Adams
et al., 2001). This neurochemical mechanism might be a starting
point to understand the increased vulnerability of the aging hip-
pocampus and decreased efficiency of HRT when administered
later in menopausal transition or menopause and subsequently
attenuated cognitive performance. Furthermore, perimenopausal
estrogen depletion and greater activity of MAO-A are risk factors
for Alzheimer’s disease (Burke et al., 2004). When estrogen ther-
apy is used early in menopausal transition, it can protect against
dementia (Zandi et al., 2002).
To which extent mood is affected by HRT remains contro-
versial. Estrogen has multifaceted neuromodulating effects and a
particular emphasis has been placed on the interaction with the
serotonergic system for some of the potential antidepressant ben-
efits estrogen use in HRT may have for women during specific
windows of time: Some studies suggest that estrogen might be
useful to target perimenopausal (Schmidt et al., 2000; Soares et al.,
2001), but not postmenopausal (Morrison et al., 2004).
Evidence from neuroimaging findings to link estrogen and the
serotonergic system in humans are still relatively sparse. Animal
data support ovariectomy to decrease 5-HT1 binding (Biegon and
McEwen, 1982), 5-HT2A binding and expression (Sumner and
Fink, 1993), and 5-HT transporter binding sites and expression
(McQueen et al., 1997; Sanchez et al., 2013). These findings have
been shown to be reversible with estrogen replacement therapy.
However, interpretation of these animal data is constrained by
the fact that they demonstrate specificity according to species,
a certain brain area and a specific neurodevelopment stage. In
humans, a recent PET study found no significant 5-HT1A binding
changes in postmenopausal women after estrogen or combined
estrogen/progesterone treatment in any of the investigated brain
regions including amygdala, ACC, hippocampus and prefrontal
cortex (Kranz et al., 2014). A short course of estrogen can increase
cortical 5-HT2A receptor density in healthy postmenopausal
women’s prefrontal regions (Kugaya et al., 2003). However, it still
remains unclear to what extent these receptor density changes
relate to clinical outcome as this study was done in healthy women
and although the increase of 5-HT2A density was paralleled by
improved performance in verbal fluency and in the trail mak-
ing task, no significant changes in mood was observed (Kugaya
et al., 2003). In contrast to short time estrogen administration,
long-term estrogen treatment seems to be associated with lower
5-HT2A receptor availability in hippocampus (Compton et al.,
2008), a finding speculated to reflect increased activity within
the serotonergic system leading to a down-regulation in post-
synaptic 5-HT2A receptor density. Again, the behavioral inter-
pretation of these findings is difficult as a negative correlation
between 5-HT2A receptor availability and memory performance
in postmenopausal females using long-term estrogen treatment
(ET) has been found while the assessed depression scores did
not differ between postmenopausal ET never-users and ET users
(Compton et al., 2008). So far, no human in vivo PET study
has investigated the effects of HRT on 5-HT-transporter binding.
More translational work needs to be carried out before a con-
clusion regarding the role of estrogen replacement therapy as a
potential mood enhancing strategy can be reached.
In summary, promising therapeutic approaches to improve
perimenopausal mood and to counter depressive symptoms
include strategies like inhibiting MAO-A, increasing multiple
monoamines with antidepressants, and administering dietary
amino acids that are precursors for the monoamines metabolized
by MAO-A (Rekkas et al., 2014; Sacher et al., 2014). Regarding
cognition, the use of HRT remains controversial. Many studies
report only small effects on cognition such as verbal memory and
attention (Hogervorst et al., 2000;Weber et al., 2014). These small
effects on cognition and the potential side effects of HRT have
to be carefully weighted. Unopposed estrogen cannot be used
for extended periods due to the increased risk of endometrial
hyperplasia (Furness et al., 2009) and malignancy (Weiderpass
et al., 1999). To counter these potential side effects, progestin is
normally added in oral contraceptive pills and HRT for endome-
trial protection (Weiderpass et al., 1999). However, the added
progestin may worsen mood in some women (Backstrom et al.,
2011). A concept also warranting further research is the target-
ing of estrogen receptors in a tissue-specific way using selective
estrogen receptor modulators (Gambacciani, 2013; Mirkin et al.,
2014). In conclusion, therapeutic use of HRT should be carefully
considered in the context of perimenopausal symptom severity,
age and prior history of HRT, dose, treatment combination, and
timing of administration.
Menstrual cycle associated mood disturbances
The spectrum of severity in mood fluctuations throughout the
menstrual cycle is wide and ranges from reports of less well-
being in the premenstrual phase to severe clinical data on suicidal
behavior: an evaluation of 44 studies in fertile women found
a positive correlation between suicide attempts and menstrual
phases that are characterized by low estrogen levels (Saunders
and Hawton, 2006). In healthy women, some studies report
negative premenstrual changes in mood as common and sug-
gest that the majority of women of reproductive age describe a
cycle-dependent increase in negative emotions, such as irritabil-
ity, impulsivity, fear, and low mood (Halbreich et al., 2007), while
other authors claim that there is no substantial evidence for any
specific premenstrual negative mood syndrome in the general
population (Romans et al., 2012). A subgroup of women, how-
ever, suffer from clinical levels of premenstrual mood changes
called premenstrual dysphoric disorder (PMDD), a condition
that has recently been included in the DSM-V (Epperson et al.,
2012a). PMDD core symptoms include anxiety, irritability and
depressed mood (Epperson et al., 2012a). Symptoms occur on
average 2–3 days before onset of menses and resolve after the
onset of menstruation (Backstrom et al., 2003). PMDD symp-
toms are limited to ovulatory menstrual cycles when the corpus
luteum is present (Yen et al., 2013), thus it is reasonable to assume
that female gonadal hormones play a causative role. However, no
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consistent differences in hormonal fluctuations during the men-
strual cycle between women experiencing clinical level PMDD
and normal controls have been found (Backstrom et al., 2003).
Although the levels of sex hormones do not differ between
PMDD and healthy women, there might be an altered genetic
susceptibility to affective dysregulation induced by normal sex
hormone levels. Preliminary genetic findings state an associ-
ation between allelic variants in the estrogen receptor alpha
gene (ESR2) and PMDD (Woods et al., 2000). As PMDD is
a heritable disorder with non-Mendelian pattern (Bayer and
Hausmann, 2010), elucidating the underlying genetic variations
and the multiple interacting genes that confer increased suscepti-
bility may improve our understanding of how PMDD symptoms
develop.
Evidence for an interaction between the altered ESR2 in
PMDD and catechol-o-methyltransferase (COMT) Val/Val geno-
type has been reported in a human haplotype analysis of 91
women with PMDD and 56 controls (Woods et al., 2000).
COMT is an enzyme involved in multiple functions, such as
estrogen metabolism (Hay et al., 1994) and has been hypothe-
sized to tune prefrontal cortical activation through the regulation
of dopamine levels (Belelli et al., 2006). The Val/Val genotype
has been associated with decreased dopamine levels in the PFC
and tuning efficiency (Soares, 2014). Thus, the authors specu-
late that a Val/Val genotype accompanied by an ESR2 variation
might be a factor that could increase the susceptibility toward
a dysphoric state via decreased PFC efficiency and disinhibited
subcortical activity. Replication of this finding in a larger sample
size, as well as the implementation of a neuroimaging protocol
to explore the PFC-amygdala circuit in parallel with a detailed
assessment of PMDD symptoms will be needed to further test this
hypothesis.
While the magnitude of hormonal fluctuation does not seem
significantly altered in women suffering from PMDD, an altered
brain response to normal hormonal fluctuation could explain the
changes in mood and behavior. Several lines of evidence sup-
port this concept: preliminary in vivo evidence from a small pilot
(PET) study in five women with PMDD has shown that rela-
tive to healthy controls, women with PMDD experience a smaller
change in 5-HT-receptor 1A binding throughout the menstrual
cycle (Jovanovic et al., 2006). In animal models of hormonally
induced depression via progesterone withdrawal, depression-like
behavior can be modulated through specific serotonergic mecha-
nisms or receptor subtypes respectively. Li and colleagues report
that activation of 5-HT1A receptors or inhibition of 5-HT3 recep-
tors rapidly decreases immobility in the forced swim test (FST),
a prominent model for assessing antidepressant-like behavior in
rodents. The FST differentiates between active (swimming and
climbing) and passive (immobility) behavior when rodents are
forced to swim in a cylinder with no escape options. Conversely,
blocking 5-HT1A receptors, activating 5-HT3 receptors, or 5-HT7
receptors increased depression-like behavior in rats in the FST (Li
et al., 2013).
The 5-HTT mediates the recapture of serotonin from the
synaptic cleft back into the cell. It is the therapeutic target of
the currently most widely prescribed class of antidepressants: the
SSRI. SSRIs have been found to be more effective in treating
premenstrual symptoms than other non-SSRI drugs or a placebo
(Dimmock et al., 2000; Shah et al., 2008). It is of particular
interest that the pattern of response to drug therapy is different
in patients with PMDD compared to patients suffering from a
MDE. PMDD patients respond within the first menstrual cycle
to SSRI-treatment (Halbreich and Kahn, 2003), suggesting that
an imbalance in the serotonergic system may be of particular
relevance to the development of PMDD symptoms.
In the context of serotonergic alternations in PMDD, BDNF
has also been implicated. Depression has been shown to be asso-
ciated with decreased BDNF expression, which can be reversed
by antidepressant treatment (Lopez et al., 2013). In a study by
Oral and colleagues, PMDD women are associated with increased
BDNF levels and increased heat-shock protein 70 (HSP70) lev-
els in the luteal phase compared with controls (Oral et al., 2013).
These findings seem contrary to the previous findings by Lopez
et al. However, Oral et al. discuss the possibility that increased
HSP70 levels, as a molecular defense mediator against proteotoxic
stress, might reflect cellular distress in PMDD women and that
the respectively increased BDNF levels could be a compensatory
mechanism potentially leading to resolved PMDD symptoms in
the follicular phase. These compensatory mechanisms seem to
fail in depressed patients. Findings of a recent study suggest
a relationship between a specific BDNF polymorphism (BDNF
Val66Met) and impaired fronto-cingulate cortex activation in
response to an emotion processing task displaying angry or fear-
ful emotions in the luteal phase of PMDDwomen (Comasco et al.,
2014). As this interaction just appears to be present in the luteal
phase, Comasco and colleagues suggest declining progesterone
levels to trigger this phenomenon and discuss these changing pro-
gesterone levels to act via direct or chloride pump-mediated influ-
ence of BDNF on the GABAergic system. Furthermore, the BDNF
Met allele lowers the sensitivity to 5-HT signaling (Martinowich
and Lu, 2008), which may influence antidepressant efficacy in
PMDD women (Comasco et al., 2014). Martinowich and Lu
hypothesize that an increase in extracellular 5-HT, for instance
after SSRI use, might increase BDNF levels because inhibition
of 5-HTT facilitates serotonergic transmission through 5-HT4,6,7
receptor subtypes (Martinowich and Lu, 2008).
Progesterone withdrawal associated with allopregnanolone
increase in the luteal phase of the menstrual cycle has been
hypothesized to be implicated in PMDD (Backstrom et al., 2011,
2014). Allopregnanolone is known for its similarities with ben-
zodiazepines (Majewska et al., 1986), which can cause drowsi-
ness, poor concentration, and memory impairment (Holbrook
et al., 2000). Therefore, heightened allopregnanolone levels
have been hypothesized to exhibit similar effects in the brain
(Backstrom et al., 2014). Contrary to this hypothesis, a study
by Girdler and colleagues found lower luteal phase allopreg-
nanolone levels in PMDD patients with higher anxiety and
irritability scores (Girdler et al., 2001). Furthermore, greater
luteal phase allopregnanolone concentrations have been shown
to be associated with improved symptom ratings in PMDD
patients (Wang et al., 1996). A possible explanation for these
unexpected findings has been proposed by Backstrom and col-
leagues: PMDD symptom severity seems to be related to allo-
pregnanolone serum concentration in an inverted U-shaped
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curve (Backstrom et al., 2011). Negative mood symptoms occur
when the serum concentration of allopregnanolone is similar to
endogenous luteal phase levels, while low and high concentra-
tions have less effect on mood (Backstrom et al., 2014). This
recent hypothesis is extended by the suggestion that negative
mood symptoms in women with PMDD could be caused by
an increased GABAA receptor sensitivity to allopregnanolone
(Backstrom et al., 2014). Allopregnanolone levels have also been
reported to increase in the brain after acute and chronic treat-
ment with SSRIs (Lovick, 2013), providing evidence for a direct
or indirect connection of allopregnanolone with the seroton-
ergic system. The mechanism by which SSRIs increases allo-
pregnanolone levels is thought to involve direct stimulation
of 3α-hydroxysteroid dehydrogenase (3α-HSD), an important
enzyme in the allopregnanolone biosynthesis (Compagnone and
Mellon, 2000). Not only the susceptibility of the GABAergic sys-
tem toward allopregnanolone seems to be altered in PMDD,
GABA levels might also be abnormal. For instance, Epperson
and colleagues found a reduction in the cortical GABA lev-
els during the follicular phase in those with PMDD compared
with healthy controls (Epperson et al., 2002). In healthy women,
cortical GABA levels fluctuate across the menstrual cycle with
decreasing levels from the follicular phase to the luteal phase,
whereas the opposite occurred in PMDDwomen (Epperson et al.,
2002).
CONCLUSIONS AND PERSPECTIVES
Pharmacological and behavioral approaches have been com-
bined to demonstrate the critical role of sex steroid hor-
mones in mediating effects on synaptic plasticity, memory,
mood, and cognition. Several studies have taken advantage of
available selective pharmacological tools and knockout mice to
elucidate the underlying molecular mechanism of the observed
behavioral and electrophysiological effects. These underlying
mechanisms are complicated. Many of them involve rapid
non-genomic action on presynaptic receptors like D1 recep-
tors, NMDA receptors, and GABAA receptors. Furthermore,
sex hormones act on multiple levels, simultaneously, as well
as the interacting neurotransmitter systems that are largely
interwoven.
Depending on the neurotransmitter system, sex hormone can
exhibit facilitative, excitatory or suppressive, inhibitory effects on
neurotransmission. For instance, progesterone has been shown
to suppress the excitatory glutamate response (Hausmann and
Gunturkun, 2000) and facilitates GABAergic neurotransmission
through its action at GABAA receptors (van Wingen et al., 2008),
while estrogen exhibits facilitating effects on glutamate transmis-
sion (Smith and Woolley, 2004) and suppresses GABA inhibitory
inputs. The promoting effect of estrogen on glutamatergic neu-
rotransmission, especially at NMDA receptors (Gazzaley et al.,
1996; Woolley et al., 1997; Adams et al., 2004), is the incit-
ing factor for synaptic plasticity and subsequently learning and
memory (Foy et al., 1999). Furthermore, estrogen is known
to promote dopamine release in the striatum, which might be
mediated by the inhibitory effect of estrogen on GABA release,
as dopamine terminals are influenced by GABAergic inputs.
Thus, a decrease in inhibitory tone might facilitate DA release.
This interaction between excitation and inhibition modulated
by sex hormones is a key factor for understanding how sex
hormones impact neuronal activity in the brain. Estrogen may
produce its mentioned effects on cognition and mood especially
through modulation of serotonergic function (Epperson et al.,
2012b). Estrogen can increase serotonin levels and decrease 5-HT
reuptake (Koldzic-Zivanovic et al., 2004), which allows 5-HT to
FIGURE 2 | Vulnerability for development of a depressive illness
corresponds to main hormonal transitions across the female lifespan.
During childhood (0–9 years), a phase associated with low estrogen
plasma levels, the prevalence rate for depression ranges between 2 and
3% (Kashani et al., 1983; Lewinsohn et al., 1994). When estrogen levels
start rising in puberty (10–15 years), so does the prevalence rate for
depression, up to 8% (Angold et al., 1998). During reproductive years, a
phase when estrogen and progesterone levels peak, prevalence rates
vary between 21 and 38% (Kessler et al., 1993; Angold et al., 1998).
Estrogen and progesterone levels start declining during perimenopause
(41–51 years), drop considerably postmenopausally (45–65 years) and
remain fairly stable during old age (above 65 years). This drop in sex
steroid levels is paralleled by a decrease in prevalence rates for
depression from 23 to 26% (Cohen et al., 2006a; Freeman et al., 2006;
Unsal et al., 2011; Tamaria et al., 2013) during the hormonal transition
phases to rates of 1–5% during old age (Tamaria et al., 2013).
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remain longer in the synaptic cleft and exhibit prolonged effects
on postsynaptic receptors.
Variations in hormone levels across the human lifespan exhibit
pivotal actions in the human body and seem to heighten the
risk of developing certain mood disorder and neurodegenerative
pathologies. For women, hormonal transitions such as postpar-
tum, menopause, and subtle fluctuations across the menstrual
cycle seem to predispose women to mood disturbance (Figure 2),
beginning with a heightened risk of developing a depressive
episode following puberty (Soares and Zitek, 2008). Beyond the
scope of postpartum or perimenopausal ovarian hormone loss,
women can be also be more vulnerable on a monthly basis,
across the menstrual cycle. Times of sex hormone withdrawal, as
seen before onset of menses, are likely to predispose women to
menstrual cycle related diseases such as PMDD.
To summarize, neurotransmitter systems do not work in isola-
tion and sex hormones act on multiple sites, highly intertwined
with serotonin, dopamine, GABA and glutamate. Fluctuating
hormone levels across the human lifespan may be particularly
significant for the etiology of neuropsychiatric diseases that dis-
play a prominent sexual dimorphism, such as Alzheimer’s disease
and depression. A better understanding of the underlying mech-
anisms that focus on activation of sex steroid specific pathways
that could contribute to individual vulnerability to such diseases
might allow for more effective treatment and prevention in the
future.
Promising approaches include the targeting of estrogen recep-
tors in a tissue-specific way using selective estrogen receptor
modulators (Gambacciani, 2013; Mirkin et al., 2014). Further
studies are on how treatment responses differ between different
hormonal states. Promising future strategies involve the inte-
gration of basic with clinical neuroscience research, drawing
resources from postmortem work, and innovative animal mod-
els for sex hormone associated affective disorders, such as the
mouse model for PPD (Galea et al., 2008) to inform human
in vivo neuroimaging experiments in health and disease. Such
human neuroimaging studies could benefit from the application
of the recently developedMR-PET hybrid scanners that allows for
a combination of fMRI and PET, and could also accommodate
real-time pharmacological interventions.
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